MedTrace Logo

The Efficacy of Ticagrelor on Abdominal Aortic Aneurysm (AAA) Expansion

NCT02070653 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 145

Last updated 2018-05-02

No results posted yet for this study

Summary

Abdominal aortic aneurysm (AAA) is a major health problem and ruptured AAA is a common cause of death in Europe and North America. A key limitation of contemporary treatment strategies of AAA is the lack of therapy directed at reducing expansion. Although surgical repair is an effective treatment for large AAA, it is associated with significant mortality and morbidity as well as substantial cost. The rationale for this randomized controlled study is to investigate whether treatment with Ticagrelor inhibits growth of small abdominal aortic aneurysms.

Conditions

  • Abdominal Aortic Aneurysm

Interventions

DRUG

Ticagrelor

DRUG

Placebo

Sponsors & Collaborators

  • AstraZeneca

    collaborator INDUSTRY

  • Uppsala University

    lead OTHER

Principal Investigators

  • Anders Wanhainen, MD. PhD · Uppsala University, Sweden

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-03-31
Primary Completion
2016-07-31
Completion
2017-07-31

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02070653 on ClinicalTrials.gov